Gilead Sciences, Inc (GILD) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Gilead Sciences, Inc, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track GILD live on Mooboard →

Next 30 days2

  • Sep 2026
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan-hziy (SG) · Phase 2 · Non-small Cell Lung Cancer
    NCT05186974: Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2026
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    TAF · Phase 2 · Chronic Hepatitis B
    NCT02932150: Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection. Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days1

  • Oct 2026
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan-hziy · Phase 2 · Solid Tumor
    NCT05119907: Study of Sacituzumab Govitecan in Patients With Solid Tumor. Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later22

  • Dec 2026
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan-hziy · Phase 3 · Metastatic Breast Cancer
    NCT04639986: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC). Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 2027
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Tilpisertib Fosmecarbil · Phase 2 · Ulcerative Colitis
    NCT06029972: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis. Primary completion 2027-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 2027
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan-hziy · Phase 3 · Triple Negative Breast Cancer; PD-L1 Positive
    NCT05382286: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer. Primary completion 2027-02 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 2027
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Oral Lenacapavir · Phase 2 · HIV-1-infection
    NCT06749054: Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children. Primary completion 2027-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 2027
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan-hziy · Phase 1 / Phase 2 · Advanced Solid Tumor; Metastatic Triple-Negative Breast Cancer
    NCT05101096: Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors. Primary completion 2027-05 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2027
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab govitecan-hziy (SG) · Phase 3 · Triple Negative Breast Cancer
    NCT05633654: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63). Primary completion 2027-06 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 2027
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    GS-3242 Tablet · Phase 2 · HIV-1-infection
    NCT07645287: A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1. Primary completion 2027-08 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 2027
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Domvanalimab · Phase 2 · Advanced Non-Small Cell Lung Cancer
    NCT05676931: Study With Various Immunotherapy Treatments in Participants With Lung Cancer. Primary completion 2027-12 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Lepetegravir · Phase 2 / Phase 3 · HIV-1-Infection
    NCT06544733: Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed. Primary completion 2028-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Lenacapavir Injection · Phase 2 · Pre-Exposure Prophylaxis of HIV Infection
    NCT06101342: Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103). Primary completion 2028-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan-hziy · Phase 3 · Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer
    NCT05840211: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy. Primary completion 2028-04 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan-hziy (SG) · Phase 1 / Phase 2 · Triple Negative Breast Cancer
    NCT06926920: A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer. Primary completion 2028-06 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Zimberelimab · Phase 3 · Non-small Cell Lung Cancer
    NCT05502237: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer. Primary completion 2028-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan-hziy · Phase 3 · Triple Negative Breast Cancer; PD-L1 Negative
    NCT05382299: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer. Primary completion 2028-07 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Lenacapavir Injection · Phase 3 · HIV Pre-exposure Prophylaxis
    NCT07047716: Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP). Primary completion 2028-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Seladelpar 5 mg Capsule · Phase 3 · Primary Biliary Cirrhosis
    NCT03301506: Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC). Primary completion 2028-11 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 2028
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Denikitug · Phase 2 · Advanced Microsatellite Stable Colorectal Cancer
    NCT07527858: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer. Primary completion 2028-12 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 2029
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Lenacapavir · Phase 3 · HIV-1-infection
    NCT07683000: Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens. Primary completion 2029-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 2029
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Lenacapavir · Phase 3 · HIV Infections
    NCT07682961: Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy. Primary completion 2029-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2029
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab govitecan-hziy · Phase 3 · Endometrial Cancer
    NCT06486441: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26). Primary completion 2029-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2029
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Zimberelimab (ZIM) · Phase 2 · Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer
    NCT05633667: Study of Novel Treatment Combinations in Patients With Lung Cancer. Primary completion 2029-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 2029
    Gilead Sciences, Inc(GILD)Phase 2/3 readout
    Sacituzumab Govitecan (SG) · Phase 3 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
    NCT06801834: Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer. Primary completion 2029-10 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Gilead Sciences, Inc has moved — past-year price reactions

How binary is GILD? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1%
typical day (1Y)
0
±10% days
26%
annualized vol
250
trading days
Largest single-day moves
  • +5.8%2026-02-11no matched headline
  • +5.2%2026-07-07no matched headline
  • +4.2%2025-10-17no matched headline
  • +4.2%2026-07-02no matched headline
  • +4%2026-01-21no matched headline
  • +3.7%2025-11-11no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Gilead Sciences, Inc — active clinical pipeline

Gilead Sciences, Inc's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

40 assets59 programsPh1 13Ph2 22Ph3 23· 1 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicInfectiousOther
Sacituzumab Govitecan-hziyOncology · TROP2 ADC
Phase 1
Advanced or Metastatic Solid Tumor
Phase 2
Advanced Solid TumorMetastatic Solid TumorMetastatic Triple-negative Breast CancerMetastatic Urothelial CancerSolid Tumor
Phase 3
Endometrial CancerLocally Advanced or Unresectable Metastatic Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer (2)
Sacituzumab Govitecan-hziy (SG)Oncology · TROP2 ADC
Phase 2
Non-small Cell Lung CancerTriple Negative Breast Cancer
Phase 3
Non-Small Cell Lung CancerTriple Negative Breast Cancer
GS-3242 TabletInfectious
Phase 2
HIV-1-infection
Phase 3
HIV-1-infection
LenacapavirInfectious · gag
Phase 3
HIV InfectionsHIV-1-infection (2)
Lenacapavir InjectionInfectious
Phase 2
Pre-Exposure Prophylaxis of HIV Infection (2)
Phase 3
HIV Pre-exposure Prophylaxis
Oral LenacapavirInfectious
Phase 2
HIV-1-infection
Phase 3
HIV-1-infection
ATVImmunology
Phase 3
Acquired Immune Deficiency Syndrome (AIDS)
B/F/TAF (Adult Strength)Infectious
Phase 3
HIV-1 Infection
BictegravirInfectious · HIV integrase
Phase 3
HIV-1-infection (2)
F/TAFInfectious
Phase 3
Pre-Exposure Prophylaxis of HIV-1 Infection
ISL/LENInfectious
Phase 3
HIV-1-Infection (2)
LepetegravirInfectious
Phase 3
HIV-1-Infection
Oral Lenacapavir (LEN)Infectious
Phase 3
Pre-Exposure Prophylaxis of HIV Infection (2)
Sacituzumab Govitecan (SG)Oncology · TROP2 ADC
Phase 3
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
SeladelparOther · PPARD
Phase 3
Primary Biliary Cholangitis
Seladelpar 5 mg CapsuleOther · PPARD
Phase 3
Primary Biliary Cirrhosis
Tenofovir DFInfectious · HIV RT
Phase 3
Chronic Hepatitis B
ZimberelimabOncology · PD-1
Phase 3
Non-small Cell Lung Cancer
DenikitugOncology
Phase 1
Advanced Solid Tumor
Phase 2
Advanced Microsatellite Stable Colorectal CancerHER2-negative
DomvanalimabOncology · TIGIT
Phase 2
Advanced Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma
emvistegrastAutoimmune
Phase 2
Ulcerative Colitis
GS-4321Infectious
Phase 2
Chronic Hepatitis Delta
ISLInfectious
Phase 2
HIV-1 Infection
Lenacapavir TabletInfectious
Phase 2
Pre-Exposure Prophylaxis of HIV Infection
TAFInfectious
Phase 2
Chronic Hepatitis B
TeropavimabInfectious
Phase 2
HIV-1 Infection
Tilpisertib FosmecarbilAutoimmune
Phase 2
Ulcerative Colitis
Zimberelimab (ZIM)Oncology · PD-1
Phase 2
Lung Cancer
B/F/TAFInfectious
Phase 1
HIV-1-infection
GS-0151Autoimmune
Phase 1
Rheumatoid Arthritis
GS-0201Oncology
Phase 1
Advanced Solid Tumors
GS-0415Infectious
Phase 1
HIV -1 Infection
GS-1206Oncology
Phase 1
Solid Tumor
GS-2121Oncology
Phase 1
Advanced Solid Tumors
GS-2426Oncology
Phase 1
Advanced Solid Tumors
GS-4528Oncology
Phase 1
Solid Tumor
GS-4571Metabolic
Phase 1
Weight Management
GS-5319Oncology
Phase 1
Advanced Solid Tumor
GS-9911Oncology
Phase 1
Solid Tumors

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.